The Value of In Vitro Dissolution in Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Value of In Vitro Dissolution in Drug Development
A Position Paper from the AAPS In Vitro Release and Dissolution Focus Group


Pharmaceutical Technology
Volume 33, Issue 4, pp. 52-64

With the challenges associated with IVIVC, especially for IR dosage forms, IVIVR should be increasingly leveraged to support design-space development. IVIVR can be manifested in two general cases: (1) in vivo performance can be tuned by in vitro dissolution; and (2) dissolution guarantees in vivo performance. In the former case, dissolution has been used to guide formulation and process development and is linked to the product and process design space. The latter case may be more valuable in the future for those drug-development paradigms in which conventional IVIVC and IVIVR are not likely or are impossible to achieve. To ensure that dissolution guarantees in vivo performance, one needs to consider the dissolution method design and drug absorption rate (ADME—absorption, distribution, metabolism, and excretion). The dissolution at least should be mapped over the entire range of physiological pH. The method conditions should mimic the in vivo environment where the drug is likely to be absorbed (11).


Figure 3. (FIGURES ARE COURTESY OF THE AUTHORS.)
Understanding dissolution and its mechanism should be integral to any method development. BCS provides a scientific foundation for dissolution and its role in the drug-absorption process (12). The dissolution process generally consists of disintegration and drug-particle solubilization. Dissolution is a general test and reflects on properties of the formulation and API (see Figure 3). In most cases for oral IR or controlled-release dosage forms, however, the rate of dissolution is controlled by specific formulation or API properties, and these properties can be monitored by specific tests and controlled either in the raw materials or during the manufacturing process using process analytical technology (PAT) tools. From a QbD perspective, the dissolution test adds limited value in these cases and should be eliminated from product-release testing.

Value of dissolution testing: Phase III clinical development

The primary objectives of Phase III development are to provide clinical supplies, generate formulation and manufacturing process knowledge for regulatory submission and approval, and help prepare for a successful, commercial product launch. To achieve these goals, it is necessary to optimize and finalize robust API and drug-product manufacturing processes, initiate long-term stability studies, and conduct pivotal bioequivalence/bioavailability (BE/BA) studies bridging Phase II and III clinical supplies and commercial product. Ideally, in vitro drug-product performance tests such as dissolution or related techniques (e.g., disintegration) should serve as a surrogate for in vivo bioavailability and as a predictor of the product's clinical performance. Development of a dissolution method may warrant significant and exhaustive evaluation of dissolution profiles in multiple apparatus and media. When process is controlled within the design space, a dissolution test may not be needed for a finished-product specification or may be replaced by other surrogate tests based on the understanding of the dissolution mechanism in Phase II clinical development. Improvements to the dissolution test method, including replacement with an appropriate surrogate test, may occur after product commercialization.

Discussion in this section focuses on where dissolution testing can add value to Phase III development. These areas include the use of dissolution testing for:

  • Process development and optimization
  • Demonstration of bioequivalence between formulations
  • Performance testing of quality control.

Process development and optimization

During Phase III development, QbD approaches can be used to optimize and finalize the drug-product formulation and manufacturing processes. Compared with conventional development approaches, QbD is primarily devoted to increasing the mechanistic understanding of a formulation and its manufacturing processes, their relationship to product quality attributes, and ultimately, their impact on the safety and efficacy of the product. When a QbD approach is selected, robust product formulation and manufacturing processes should be designed to achieve desired product performance and also relate to desired clinical performance. When the product performance can be appropriately characterized by in vitro dissolution (or a surrogate) test, the dissolution test can be a powerful tool. In the latter case, the dissolution test may use multivariate analysis to evaluate parameters that can affect drug-product performance, thus assisting in the identification of critical quality attributes and critical process parameters.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here